Multiple Myeloma News
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Antithrombotic Treatment Resistance in Multiple Myeloma Likely Multifactorial
Source: Myeloma - Hematology Advisor Researchers sought to determine the factors involved in the resistance to antithrombotic therapy that is observed among patients with multiple myeloma. Read More
Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Source: Myeloma - Hematology Advisor Post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone (KRd) improves outcomes, when compared with lenalidomide alone, in patients with multiple myeloma (MM), according to research presented at the EHA 2022...
Dara-KRD Induction Effective in High-Risk, Newly Diagnosed Myeloma
Source: Myeloma - Hematology Advisor Among some patients with transplant-eligible, newly diagnosed multiple myeloma (MM), a daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRD) induction regimen is both safe and yields deep responses prior to...
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
Source: Myeloma : nature.com subject feeds Post Content Read More
Factors Related to Adherence to Oral Multiple Myeloma Therapy
Source: Myeloma - Hematology Advisor Lack of adherence to cancer treatment using oral therapies can contribute to poor treatment outcomes, and a team of researchers conducted a study to investigate factors that may be related to lack of adherence to oral agents....
Post-Transplant Carfilzomib, Lenalidomide, and Dexamethasone May Be New Standard of Care in Multiple Myeloma
Source: Myeloma - Hematology Advisor Minimal residual disease (MRD)/risk-adapted post-transplant carfilzomib, lenalidomide, and dexamethasone (KRd) therapy demonstrated superior progression-free survival (PFS) compared with lenalidomide (R) maintenance therapy in...
IKEMA Update Reveals “Unprecedented” PFS in Relapsed Multiple Myeloma
Source: Myeloma - Hematology Advisor New data support isatuximab plus carfilzomib and dexamethasone (Isa-Kd) as standard care for relapsed multiple myeloma (MM), according to researchers. Updated data from the IKEMA trial showed that adding Isa to Kd significantly...